+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli



Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli



International Journal of Antimicrobial Agents 26(3): 254-257



This study was conducted to assess the clinical outcomes of bloodstream infections caused by extended-spectrum P-lactamase-producing Escherichia coli. A total of 53 patients were included in the study. Forty-five patients (84.9%) received appropriate antibiotic therapy. Initial empirical treatment was appropriate in 12 patients, whereas the antibiotic was changed according to susceptibility results in the remaining 33 patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 011865601

Download citation: RISBibTeXText

PMID: 16122910

DOI: 10.1016/j.ijantimicag.2005.06.012


Related references

Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. International Journal of Antimicrobial Agents 42(5): 403-409, 2014

Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131. Microbial Drug Resistance 21(4): 463-469, 2016

Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. European Journal of Clinical Microbiology & Infectious Diseases 27(1): 85-88, 2007

Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clinical Microbiology and Infection 14(2): 180-183, 2007

Therapeutic options for bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clinical Infectious Diseases 51(1): 119-20; Author Reply 120-1, 2010

Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Journal of Microbiology, Immunology, and Infection, 2015

Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Journal of Clinical Microbiology 48(5): 1726-1731, 2010

Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 115(4): 942-949, 2005

Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infection Control and Hospital Epidemiology 25(10): 860-867, 2004

Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrobial Agents and ChemoTherapy 52(9): 3244-3252, 2008

Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-beta-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli. 2012

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrobial Agents and ChemoTherapy 46(5): 1481-1491, 2002

Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrobial Agents and ChemoTherapy 54(9): 4006-4008, 2010

Bloodstream infections by extended spectrum beta-lactamase -producing Escherichia coli and Klebsiella pneumoniae in children Epidemiologic investigation and clinical outcome. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 420, 2001